Brief: Durect Corporation Announces Last Patient Last Visit In Phase 2B Ahfirm Trial Of Larsucosterol In Alcohol-Associated Hepatitis
07/09/2023 13:25
Sept 7 (Reuters) - DURECT Corp DRRX.O :
* DURECT CORPORATION ANNOUNCES LAST PATIENT LAST VISIT IN
PHASE 2B
AHFIRM TRIAL OF LARSUCOSTEROL IN ALCOHOL-ASSOCIATED HEPATITIS
* DURECT CORP- COMPANY ON TRACK TO REPORT TOPLINE DATA FROM
AHFIRM
IN Q4 2023
Source text for Eikon: ID:nPn6cgQtCa
Further company coverage: DRRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DURECT
See all newsBrief: Bausch Health Completes Acquisition Of Durect Corporation, Expanding Late-Stage Liver Disease Portfolio
Durect Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: Durect Bausch Health Extend Tender Offer Date To Aug 12 - SEC Filing
Durect Corp Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
Durect Corp Reports Results For The Quarter Ended March 31: Earnings Summary